| GO ID | Ontology | GO Term | Term Definition |
Proteins |
GO:0010891 | BP | negative regulation of sequestering of triglyceride | Any process that modulates the rate, frequency or extent of sequestering of triglyceride. Triglyceride sequestration is the process of binding or confining any triester of glycerol such that it is separated from other components of a biological system. |
PPARG, PPARA, ABHD5, PNPLA2, OSBPL8 |
GO:0010894 | BP | negative regulation of steroid biosynthetic process | Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus. |
INSIG1, BMP2 |
GO:0010897 | BP | negative regulation of triglyceride catabolic process | Any process that decreases the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of triglyceride. |
APOC3, PIK3CG, GPLD1, PLIN5 |
GO:0010898 | BP | positive regulation of triglyceride catabolic process | Any process that increases the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of triglyceride. |
APOA1, AADAC, APOA5, ABHD5, PNPLA2 |
GO:0010899 | BP | regulation of phosphatidylcholine catabolic process | Any process that modulates the rate, frequency or extent of phosphatidylcholine catabolism. Phosphatidylcholine catabolic processes are the chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. |
LDLR, SCARB1 |
GO:0010900 | BP | negative regulation of phosphatidylcholine catabolic process | Any process that decreases the rate, frequency or extent of phosphatidylcholine catabolism. Phosphatidylcholine catabolic processes are the chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. |
APOC1 |
GO:0010902 | BP | positive regulation of very-low-density lipoprotein particle remodeling | Any process that increases the rate, frequency or extent of very-low-density lipoprotein particle remodeling. Very-low-density lipoprotein particle remodeling is the acquisition, loss or modification of a protein or lipid within a very-low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acid. |
APOA5 |
GO:0010903 | BP | negative regulation of very-low-density lipoprotein particle remodeling | Any process that decreases the rate, frequency or extent of very-low-density lipoprotein particle remodeling. Very-low-density lipoprotein particle remodeling is the acquisition, loss or modification of a protein or lipid within a very-low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acid. |
APOA1, APOA2, APOC3 |
GO:0010906 | BP | regulation of glucose metabolic process | Any process that modulates the rate, frequency or extent of glucose metabolism. Glucose metabolic processes are the chemical reactions and pathways involving glucose, the aldohexose gluco-hexose. |
ACACB, PARK2, IGFBP3, IGFBP4, IGFBP5, RORA, PDK1, NCOA2, ADIPOQ, PDK4, ADIPOR1, PASK, C1QTNF1, LCMT1, SIK3 |
GO:0010907 | BP | positive regulation of glucose metabolic process | Any process that increases the rate, frequency or extent of glucose metabolism. Glucose metabolic processes are the chemical reactions and pathways involving glucose, the aldohexose gluco-hexose. |
AKT1, AKT2, IRS1, GPLD1, PMAIP1, RGN, IRS2 |
GO:0010909 | BP | positive regulation of heparan sulfate proteoglycan biosynthetic process | Any process that increases the rate, frequency or extent of heparan sulfate proteoglycan biosynthesis. Heparan sulfate proteoglycan biosynthetic processes are the chemical reactions and pathways resulting in the formation of the heparan sulfate proteoglycan, a glycosaminoglycan with repeat unit consisting of alternating alpha-(1->4)-linked hexuronic acid and glucosamine residues. |
CTNNB1, PXYLP1, TCF7L2 |
GO:0010916 | BP | negative regulation of very-low-density lipoprotein particle clearance | Any process that decreases the rate, frequency or extent of very-low-density lipoprotein particle clearance. Very-low-density lipoprotein particle clearance is the process in which a very-low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded. |
APOC1, APOC3, LRPAP1 |
GO:0010917 | BP | negative regulation of mitochondrial membrane potential | Any process that stops, prevents, or reduces the frequency, rate or extent of establishment or extent of a mitochondrial membrane potential, the electric potential existing across any mitochondrial membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane. |
ARL6IP5, PMAIP1, PRELID1, HEBP2 |
GO:0010918 | BP | positive regulation of mitochondrial membrane potential | Any process that activates or increases the frequency, rate or extent of establishment or extent of a mitochondrial membrane potential, the electric potential existing across any mitochondrial membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane. |
VCP, BAD |
GO:0010922 | BP | positive regulation of phosphatase activity | Any process that increases the rate or frequency of phosphatase activity. Phosphatases catalyze the hydrolysis of phosphoric monoesters, releasing inorganic phosphate. |
BMP2, RGN |
GO:0010923 | BP | negative regulation of phosphatase activity | Any process that decreases the rate or frequency of phosphatase activity. Phosphatases catalyze the hydrolysis of phosphoric monoesters, releasing inorganic phosphate. |
URI1, MYO1D, CD2BP2, RRP1B, TMEM132D, RBM26, ARFGEF3, CNST, SPOCD1, SPRED1, ZCCHC9, CASC5, PPP1R35, SH3RF2, CSRNP3, PKMYT1, CHP1, NIFK, CCDC8, CSRNP2, WNK1, PCIF1, ZFYVE1, SYTL2, GPATCH2, CAMSAP3, TSKS, FARP1, KIAA0430 |
GO:0010933 | BP | positive regulation of macrophage tolerance induction | Any process that increases the frequency, rate, or extent of B cell tolerance induction. |
IRAK3 |
GO:0010934 | BP | macrophage cytokine production | The appearance of a macrophage cytokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. |
GAS6 |
GO:0010936 | BP | negative regulation of macrophage cytokine production | Any process that decreases the rate, frequency or extent of macrophage cytokine production. Macrophage cytokine production is the appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. |
TGFB1, TGFB2, IRAK3 |
GO:0010939 | BP | regulation of necrotic cell death | Any process that modulates the rate, frequency or extent of necrotic cell death. Necrotic cell death is a cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents. |
UBC, PPIF, RPS27A, UBA52, BIRC3, RIPK1, CASP8, TRADD |
GO:0010940 | BP | positive regulation of necrotic cell death | Any process that increases the rate, frequency or extent of necrotic cell death. Necrotic cell death is a cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents. |
MT3, TSPO, RIPK1, HEBP2 |
GO:0010941 | BP | regulation of cell death | Any process that modulates the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death. |
CRYAB, JUN, JUNB, JUND |
GO:0010942 | BP | positive regulation of cell death | Any process that increases the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death. |
PRODH, TRIM13, HP, MYCN, BMP4, MT3, PHB, AKR1C3, CDKN1B, UCP2, HBB, HBA1, KATNB1, SAP30BP, FAF1 |
GO:0010944 | BP | negative regulation of transcription by competitive promoter binding | Any process that stops, prevents, or reduces the frequency, rate or extent of DNA-dependent transcription using a mechanism that involves direct competition for interaction with a promoter binding site. |
SMAD7, MUC1, CREB1, PHB, HHEX, DACH1 |
GO:0010948 | BP | negative regulation of cell cycle process | Any process that decreases the rate, frequency or extent of a cellular process that is involved in the progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. |
GPER1 |
GO:0010949 | BP | negative regulation of intestinal phytosterol absorption | Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of phytosterols into the blood by absorption from the small intestine. |
ABCG8 |
GO:0010950 | BP | positive regulation of endopeptidase activity | Any process that increases the frequency, rate or extent of endopeptidase activity, the endohydrolysis of peptide bonds within proteins. |
SERPINB3, PSME3, ADRM1, PRELID1 |
GO:0010951 | BP | negative regulation of endopeptidase activity | Any process that decreases the frequency, rate or extent of endopeptidase activity, the endohydrolysis of peptide bonds within proteins. |
SPINT2, PAPLN, PTTG1, SERPINC1, SERPINA1, SERPINA3, AGT, A2M, C3, TIMP1, CSTA, KNG1, AMBP, AHSG, SLPI, VTN, CSTB, APP, SERPINE1, SERPINA5, SERPING1, SERPINE2, FURIN, C4A, C4B, TFPI, COL6A3, TIMP2, CAST, ANOS1, SERPINB3, PEBP1, SERPINB1, AKT1, SERPINB5, SERPINF1, TFPI2, SERPINB4, SERPINB9, SERPINH1, COL4A3, APLP2, BST2, SPP2, WFDC2, CARD16, ITIH5, WFDC3, SERPINA12, CPAMD8, SPOCK2, SERPINI1, PROL1, SPOCK3, LXN, WFDC1, CRIM1, FETUB, SERPINB13, UCHL5 |
GO:0010952 | BP | positive regulation of peptidase activity | Any process that increases the frequency, rate or extent of peptidase activity, the hydrolysis of peptide bonds within proteins. |
CLPX, FN1, APP, CTSH, FBLN1, MMP14, CAV1, PSME4, PCOLCE, PINK1, NDUFA13, PCOLCE2 |
GO:0010954 | BP | positive regulation of protein processing | Any process that increases the rate, frequency or extent of protein maturation by peptide bond cleavage. |
ADAM8, CCBE1, RHBDD1 |
GO:0010955 | BP | negative regulation of protein processing | Any process that decreases the rate, frequency or extent of protein maturation by peptide bond cleavage. |
SERPINE2, IL1R2, GAS1, MDM2, GLG1, CHAC1, TMEM59, SNX12 |
GO:0010956 | BP | negative regulation of calcidiol 1-monooxygenase activity | Any process that decreases the rate, frequency or extent of calcidiol 1-monooxygenase activity. Calcidiol 1-monooxygenase activity is the catalysis of the reaction: calcidiol + NADPH + H+ + O2 = calcitriol + NADP+ + H2O. |
CYP27B1, NFKB1 |
GO:0010957 | BP | negative regulation of vitamin D biosynthetic process | Any process that decreases the rate, frequency or extent of a vitamin D biosynthetic process. Vitamin D biosynthesis is the chemical reactions and pathways resulting in the formation of vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3). |
SNAI2, NFKB1 |
GO:0010960 | BP | magnesium ion homeostasis | Any process involved in the maintenance of an internal steady state of magnesium ions within an organism or cell. |
EGFR, KCNA1, ANK3, CNNM2 |
GO:0010961 | BP | cellular magnesium ion homeostasis | Any process involved in the maintenance of an internal steady state of magnesium ions at the level of a cell. |
TRPM7 |
GO:0010965 | BP | regulation of mitotic sister chromatid separation | Any process that modulates the frequency, rate or extent of mitotic sister chromatid separation. Mitotic sister chromatid separation is the process in which sister chromatids are physically detached from each other during mitosis. |
TPR |
GO:0010968 | BP | regulation of microtubule nucleation | Any process that modulates the rate, frequency or extent of microtubule nucleation. Microtubule nucleation is the 'de novo' formation of a microtubule, in which tubulin heterodimers form metastable oligomeric aggregates, some of which go on to support formation of a complete microtubule. Microtubule nucleation usually occurs from a specific site within a cell. |
EML2 |
GO:0010970 | BP | transport along microtubule | The movement of organelles or other particles from one location in the cell to another along microtubules. |
DCTN1 |
GO:0010971 | BP | positive regulation of G2/M transition of mitotic cell cycle | Any process that increases the rate or extent of progression from G2 phase to M phase of the mitotic cell cycle. |
CDC7, RAD51C, BRD4, VPS4B, APP, CDK4, PBX1, RAB11A, SMARCD3, DBF4B |
GO:0010972 | BP | negative regulation of G2/M transition of mitotic cell cycle | Any cell cycle regulatory process that decreases the rate or extent of progression of a cell from G2 to M phase of the mitotic cell cycle. |
FHL1 |
GO:0010975 | BP | regulation of neuron projection development | Any process that modulates the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). |
AKT1, PTEN, SNAP25, NCS1, CCDC88A, SFRP1, ULK4, NDEL1, CHODL |
GO:0010976 | BP | positive regulation of neuron projection development | Any process that increases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). |
APBB1, ENC1, PLXNB2, CBFA2T2, KDM1A, SNX3, NTRK1, IL6, FYN, LYN, FGFR1, NME1, ARSB, ATF1, CNR1, NME2, ITGA3, EPHA3, LTK, SERPINF1, WNT5A, PRKCI, ABL2, RAP1A, CNTN1, PTK7, RAPGEF1, CAMK1, SCARF1, DPYSL3, PRKD1, PPP2R5B, ANKRD1, UBE2V2, NTRK2, TWF2, FBXO38, FAM150B, SETX, MAGI2, CAMK1D, NDNF, FEZ1, KATNB1, TMEM30A, RRN3, GPRC5B, TENM3, KIDINS220, NDRG4 |
GO:0010977 | BP | negative regulation of neuron projection development | Any process that decreases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). |
RAB29, CBFA2T2, SNAPIN, NGFR, VIM, LGALS1, NR2F1, PTPRG, GSK3B, B2M, MDM2, PMP22, FKBP4, DPYSL3, SEMA3A, KANK1, PTPRO, DGUOK, HDAC2, CIB1, TRPV4, BAG5 |
GO:0010980 | BP | positive regulation of vitamin D 24-hydroxylase activity | Any process that increases the rate, frequency or extent of vitamin D 24-hydroxylase activity. Vitamin D 24-hydroxylase activity catalyzes the hydroxylation of C-24 of any form of vitamin D. |
CYP27B1, VDR |
GO:0010983 | BP | positive regulation of high-density lipoprotein particle clearance | Any process that increases the rate, frequency or extent of high-density lipoprotein particle clearance. High-density lipoprotein particle clearance is the process in which a high-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded. |
GPLD1, LIPG |
GO:0010987 | BP | negative regulation of high-density lipoprotein particle clearance | Any process that decreases the rate, frequency or extent of high-density lipoprotein particle clearance. High-density lipoprotein particle clearance is the process in which a high-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded. |
APOC3 |
GO:0010988 | BP | regulation of low-density lipoprotein particle clearance | Any process that modulates the rate, frequency or extent of low-density lipoprotein particle clearance. Low-density lipoprotein particle clearance is the process in which a low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded. |
NR1H4, CNPY2 |
GO:0010989 | BP | negative regulation of low-density lipoprotein particle clearance | Any process that decreases the rate, frequency or extent of low-density lipoprotein particle clearance. Low-density lipoprotein particle clearance is the process in which a low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded. |
APOC3, CSK, PCSK9, MYLIP |
GO:0010990 | BP | regulation of SMAD protein complex assembly | Any process that modulates the rate, frequency, or extent of SMAD protein complex assembly. SMAD protein complex assembly is the aggregation, arrangement and bonding together of a set of components to form a protein complex that contains SMAD proteins. |
PARP1 |
GO:0010991 | BP | negative regulation of SMAD protein complex assembly | Any process that decreases the rate, frequency, or extent of SMAD protein complex assembly. SMAD protein complex assembly is the aggregation, arrangement and bonding together of a set of components to form a protein complex that contains SMAD proteins. |
SMAD6, PMEPA1 |
GO:0010992 | BP | ubiquitin homeostasis | Any process involved in the maintenance of an internal steady state of ubiquitin monomers and free ubiquitin chains at the level of the cell. |
IDE |
GO:0010994 | BP | free ubiquitin chain polymerization | The process of creating free ubiquitin chains, compounds composed of a large number of ubiquitin monomers. These chains are not conjugated to a protein. |
UBE2C, PARK2, UBE2S, TRIM6 |
GO:0010996 | BP | response to auditory stimulus | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an auditory stimulus. |
IL6, XPA, XPC, ABHD12 |
GO:0010997 | MF | anaphase-promoting complex binding | Interacting selectively and non-covalently with an anaphase-promoting complex. A ubiquitin ligase complex that degrades mitotic cyclins and anaphase inhibitory protein, thereby triggering sister chromatid separation and exit from mitosis. |
PLK1, PTEN, CDC20, FZR1 |
GO:0010998 | BP | regulation of translational initiation by eIF2 alpha phosphorylation | Any process that modulates the frequency, rate or extent of translation initiation in response to stress by the phosphorylation of eIF2 alpha. |
EIF2AK4 |
GO:0012501 | BP | programmed cell death | A process which begins when a cell receives an internal or external signal and activates a series of biochemical events (signaling pathway). The process ends with the death of the cell. |
TOP1, PKM, RNF130, GSDMB |
GO:0012505 | CC | endomembrane system | A collection of membranous structures involved in transport within the cell. The main components of the endomembrane system are endoplasmic reticulum, Golgi bodies, vesicles, cell membrane and nuclear envelope. Members of the endomembrane system pass materials through each other or though the use of vesicles. |
ACACB, PIP5K1B, PGRMC2, BCL2L11, PIP5K1C, TBC1D4, SLC2A10, TBC1D8, TBC1D3H, SLC2A4, ATP6V1B2, JAK1, JAK3, RAC3, TBC1D8B, GRTP1, TBC1D9B, TBC1D3C, NBEAL1, TBC1D9, RUFY3, LAPTM4B, TBC1D3, MPP5, RHEBL1, TBC1D15, PARD3, CYB5D2, DOCK2, NSMAF, USP6NL, MAL2, RUNDC1, EVI5L, ASPSCR1, MAP1LC3B, NRBP2, AIG1, CDC42EP3, NENF, TBC1D2B, RABGAP1 |
GO:0012506 | CC | vesicle membrane | The lipid bilayer surrounding any membrane-bounded vesicle in the cell. |
SYNJ1, ANXA4, SLC2A4, ACPP, ATP2A2, CLCN3, GRB2, ASPSCR1, ATP13A2, RAB21, PIKFYVE |
GO:0012507 | CC | ER to Golgi transport vesicle membrane | The lipid bilayer surrounding a vesicle transporting substances from the endoplasmic reticulum to the Golgi. |
GOSR2, SEC22B, SEC24D, SEC31A, TGFA, HLA-B, HLA-DRA, HLA-DQA2, HLA-DQA1, HLA-DQB1, CD74, HLA-E, HLA-DRB4, FOLR1, AREG, HLA-G, HLA-DPA1, HLA-A, HLA-F, SREBF1, TMED10, SEC13, B2M, HLA-DRB3, SREBF2, TMED2, SEC23A, HLA-DRB5, MCFD2, VTI1B, SAR1B |
GO:0012510 | CC | trans-Golgi network transport vesicle membrane | The lipid bilayer surrounding a vesicle transporting substances between the trans-Golgi network and other parts of the cell. |
RASSF9 |
GO:0014002 | BP | astrocyte development | The process aimed at the progression of an astrocyte over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. An astrocyte is the most abundant type of glial cell. Astrocytes provide support for neurons and regulate the environment in which they function. |
TLR4, TSPAN2, S100A8, S100A9, VIM, MT3, PLP1, CDK6, EIF2B5, LAMC3 |
GO:0014003 | BP | oligodendrocyte development | The process aimed at the progression of an oligodendrocyte over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. An oligodendrocyte is a type of glial cell involved in myelinating the axons in the central nervous system. |
TGFB1, LYN, GSTP1, CD9, ASCL1, ID2, EIF2B5, EIF2B1, MED12, EIF2B3, EIF2B4, MYRF |
GO:0014005 | BP | microglia development | The process aimed at the progression of a microglial cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. |
TSPAN2 |
GO:0014009 | BP | glial cell proliferation | The multiplication or reproduction of glial cells by cell division, resulting in the expansion of their population. Glial cells exist throughout the nervous system, and include Schwann cells, astrocytes, and oligodendrocytes among others. |
PENK, EEF2, AREG, SOX4 |
GO:0014010 | BP | Schwann cell proliferation | The multiplication or reproduction of Schwann cells, resulting in the expansion of their population. Schwann cells are a type of glial cell in the peripheral nervous system. |
NF2 |
GO:0014012 | BP | peripheral nervous system axon regeneration | The regrowth of axons outside the central nervous system (outside the brain and spinal cord) following an axonal injury. |
APOA1, APOD, TNC, TSPO |
GO:0014013 | BP | regulation of gliogenesis | Any process that modulates the frequency, rate or extent of gliogenesis, the formation of mature glia. |
NF2, EZH2 |
GO:0014015 | BP | positive regulation of gliogenesis | Any process that activates or increases the frequency, rate or extent of gliogenesis, the formation of mature glia. |
SOX8 |
GO:0014028 | BP | notochord formation | The formation of the notochord from the chordamesoderm. The notochord is composed of large cells packed within a firm connective tissue sheath and is found in all chordates at the ventral surface of the neural tube. In vertebrates, the notochord contributes to the vertebral column. |
EFNA1 |
GO:0014029 | BP | neural crest formation | The formation of the specialized region of ectoderm between the neural ectoderm (neural plate) and non-neural ectoderm. The neural crest gives rise to the neural crest cells that migrate away from this region as neural tube formation procedes. |
LRP6 |
GO:0014031 | BP | mesenchymal cell development | The process aimed at the progression of a mesenchymal cell over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell. |
BCL2, NOTCH1, FOXC1, HEYL |
GO:0014032 | BP | neural crest cell development | The process aimed at the progression of a neural crest cell over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell. |
SNAI2, ALDH1A2, EDN1, EDNRA, BMPR1A, SOX9, NRG1, FOXC1, RDH10 |
GO:0014033 | BP | neural crest cell differentiation | The process in which a relatively unspecialized cell acquires specialized features of a neural crest cell. |
LRP6, HTR2B, MEF2C, SMAD4 |
GO:0014034 | BP | neural crest cell fate commitment | The process in which a cell becomes committed to become a neural crest cell. |
SFRP1 |
GO:0014037 | BP | Schwann cell differentiation | The process in which a relatively unspecialized cell acquires the specialized features of a Schwann cell. Schwann cells are found in the peripheral nervous system, where they insulate neurons and axons, and regulate the environment in which neurons function. |
EGR2, ERBB3, GPC1 |
GO:0014038 | BP | regulation of Schwann cell differentiation | Any process that modulates the frequency, rate or extent of Schwann cell differentiation. |
CDK1 |
GO:0014040 | BP | positive regulation of Schwann cell differentiation | Any process that activates or increases the frequency, rate or extent of Schwann cell differentiation. |
RELA, DICER1 |
GO:0014041 | BP | regulation of neuron maturation | Any process that modulates the frequency, rate or extent of neuron maturation, the process leading to the attainment of the full functional capacity of a neuron. This process is independent of morphogenetic change. |
RAC3, RAC1 |
GO:0014042 | BP | positive regulation of neuron maturation | Any process that activates or increases the frequency, rate or extent of neuron maturation. |
OPA1, BCL2 |
GO:0014043 | BP | negative regulation of neuron maturation | Any process that stops, prevents, or reduces the frequency, rate or extent of neuron maturation. |
GSK3B |
GO:0014044 | BP | Schwann cell development | The process aimed at the progression of a Schwann cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. Schwann cells are found in the peripheral nervous system, where they insulate neurons and axons, and regulate the environment in which neurons function. |
CDK5, MED12 |
GO:0014047 | BP | glutamate secretion | The controlled release of glutamate by a cell. The glutamate is the most abundant excitatory neurotransmitter in the nervous system. |
GLS, SYT1, SLC1A3, SLC1A2, SLC1A6, SNAP25, STXBP1, VAMP2, APBA1, NTRK2, TRPV1 |
GO:0014048 | BP | regulation of glutamate secretion | Any process that modulates the frequency, rate or extent of the controlled release of glutamate. |
SNCA |
GO:0014049 | BP | positive regulation of glutamate secretion | Any process that activates or increases the frequency, rate or extent of the controlled release of glutamate. |
CCK, DPYSL2 |
GO:0014050 | BP | negative regulation of glutamate secretion | Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of glutamate. |
TRH, ADORA1, NPY5R, HRH3 |
GO:0014051 | BP | gamma-aminobutyric acid secretion | The regulated release of gamma-aminobutyric acid by a cell or a tissue. The gamma-aminobutyric acid is the principal inhibitory neurotransmitter in the brain but is also found in several extraneural tissues. |
APBA1 |
GO:0014053 | BP | negative regulation of gamma-aminobutyric acid secretion | Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of gamma-aminobutyric acid. |
ABAT |
GO:0014054 | BP | positive regulation of gamma-aminobutyric acid secretion | Any process that activates or increases the frequency, rate or extent of the regulated release of gamma-aminobutyric acid. |
TRH, SLC6A1 |
GO:0014059 | BP | regulation of dopamine secretion | Any process that modulates the frequency, rate or extent of the regulated release of dopamine. |
PARK2, DRD2, SNCA |
GO:0014061 | BP | regulation of norepinephrine secretion | Any process that modulates the frequency, rate or extent of the regulated release of norepinephrine. |
AGT, CHRNA7, HRH3 |
GO:0014063 | BP | negative regulation of serotonin secretion | Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of serotonin. |
MAOB, LILRB1, HRH3 |
GO:0014065 | BP | phosphatidylinositol 3-kinase signaling | A series of reactions within the signal-receiving cell, mediated by the intracellular phosphatidylinositol 3-kinase (PI3K). Many cell surface receptor linked signaling pathways signal through PI3K to regulate numerous cellular functions. |
PIK3CD, ERBB2, IGF1, EDN1, IGF1R, ERBB3, PIK3R1, LTK, IRS1, HTR2B, PIK3CB, PIK3CG, TYRO3, C1QBP, ZFP36L1, PREX2, SIRT2 |
GO:0014066 | BP | regulation of phosphatidylinositol 3-kinase signaling | Any process that modulates the frequency, rate or extent of signal transduction mediated by the phosphatidylinositol 3-kinase cascade. |
PIK3CD, EREG, PIP5K1B, PIP5K1C, FGF18, FGF19, EGFR, PDGFB, PDGFA, ERBB2, FYN, FGF2, PDGFRB, KIT, CD28, FGFR1, VAV1, PDGFRA, KITLG, FGF7, FGFR2, ERBB3, MAPK3, PIK3R1, MAPK1, FGF9, AKT1, BTC, IRS1, PIK3CA, PIK3CB, IER3, GRB2, PIP4K2B, NRG1, PTPN11, PPP2R5C, GAB1, PPP2R5B, ERBB4, FRS2, HBEGF, KL, FBXL2, IRS2 |
GO:0014067 | BP | negative regulation of phosphatidylinositol 3-kinase signaling | Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the phosphatidylinositol 3-kinase cascade. |
KLF4, STAMBP, SERPINE2, TSC2, PTEN, TWIST1 |
GO:0014068 | BP | positive regulation of phosphatidylinositol 3-kinase signaling | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the phosphatidylinositol 3-kinase cascade. |
HAX1, JAK2, F2, AGT, PDGFB, GH1, INS, PDGFA, IGF1, FYN, DCN, PDGFRB, FGR, KIT, CD28, FGFR1, CCL5, HGF, HCLS1, PDGFRA, ERBB3, FSHR, F2R, LEP, SOX9, F2RL1, TGFB2, NRG1, TEK, PPARD, PTK2, IL18, ERBB4, ANGPT1, NTRK2, SERPINA12, UNC5B, MYDGF, GPER1, PDGFD, PDGFC |
GO:0014069 | CC | postsynaptic density | The postsynaptic density is a region that lies adjacent to the cytoplasmic face of the postsynaptic membrane at an excitatory synapse. It forms an electron-dense disc that consists of a range of proteins with different functions, some of which contact the cytoplasmic domains of ion channels in the postsynaptic membrane. The proteins making up the disc include structural proteins linked to the actin cytoskeleton and signalling machinery, such as protein kinases and phosphatases. |
DLGAP1, ADAM10, AXIN1, LZTS3, DAB1, CRYAB, FYN, LYN, FBXO45, MAPT, BCR, DRD2, IFNGR1, SYN1, GAP43, MT3, ADORA1, NSF, MAP1B, EPHA4, NCS1, DLG4, ARF1, CDK5, FMR1, SOS1, GRIN2A, EPS8, DLG1, MAPK8IP2, MTMR2, PTCH1, CACNA1C, ITPR1, GRM3, CNN3, CPEB4, NSMF, ARC, CAMK2N1, MAGI2, HOMER1, MIB1, ABI1, NLGN4X, NLGN1, MINK1, NETO2, CACNG8, PDLIM5, ALS2, GPER1, PKP4, P2RX4, SIGMAR1, SYT11, LIN7B, GOPC, HOMER3, LIN7C, PSD3, CRIPT, IGSF9B, LZTS1, PCLO |
GO:0014070 | BP | response to organic cyclic compound | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organic cyclic compound stimulus. |
ACACB, PTGES, ANGPT2, ABCC4, AMH, ICAM1, CDK1, EPHX1, LYN, G6PD, ATF1, COMT, ABCD3, ACSL1, NAMPT, MKI67, MMP14, CPT1A, LUM, BTG2, CD83, NEDD8, DUSP6, LONP2, SFRP1, PLIN2, TXN2 |
GO:0014074 | BP | response to purine-containing compound | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a purine-containing compound stimulus. |
ADSS, SLC6A1, HMGCS1, AACS |
GO:0014075 | BP | response to amine | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amine stimulus. An amine is a compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups. |
CDK1, NME1, ITGA2, CAD, HNMT |
GO:0014701 | CC | junctional sarcoplasmic reticulum membrane | The part of the sarcoplasmic reticulum membrane that contains calcium release channels, is devoted to calcium release and is juxtaposed to transverse tubule membrane. The junctional sarcoplasmic reticulum membrane consists of the junctional region of the terminal cisterna membrane. |
AKAP6, RYR2 |